145 related articles for article (PubMed ID: 19200826)
1. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer.
Venuti A; Massa S; Mett V; Vedova LD; Paolini F; Franconi R; Yusibov V
Vaccine; 2009 May; 27(25-26):3395-7. PubMed ID: 19200826
[TBL] [Abstract][Full Text] [Related]
2. Anti-cancer activity of plant-produced HPV16 E7 vaccine.
Massa S; Franconi R; Brandi R; Muller A; Mett V; Yusibov V; Venuti A
Vaccine; 2007 Apr; 25(16):3018-21. PubMed ID: 17280752
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine.
Franconi R; Massa S; Illiano E; Mullar A; Cirilli A; Accardi L; Di Bonito P; Giorgi C; Venuti A
Int J Immunopathol Pharmacol; 2006; 19(1):187-97. PubMed ID: 16569357
[TBL] [Abstract][Full Text] [Related]
4. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
[TBL] [Abstract][Full Text] [Related]
6. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
Cheung YK; Cheng SC; Sin FW; Xie Y
Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
[TBL] [Abstract][Full Text] [Related]
7. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
8. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X
Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical immunogenicity and anti-tumour efficacy of a deleted recombinant human papillomavirus type 16 E7 protein.
Hallez S; Brulet JM; Vandooren C; Maudoux F; Thomas S; Heinderickx M; Bollen A; Wattiez R; Jacquet A
Anticancer Res; 2004; 24(4):2265-75. PubMed ID: 15330171
[TBL] [Abstract][Full Text] [Related]
10. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection.
Franconi R; Di Bonito P; Dibello F; Accardi L; Muller A; Cirilli A; Simeone P; Donà MG; Venuti A; Giorgi C
Cancer Res; 2002 Jul; 62(13):3654-8. PubMed ID: 12097270
[TBL] [Abstract][Full Text] [Related]
11. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model.
Welters MJ; Filippov DV; van den Eeden SJ; Franken KL; Nouta J; Valentijn AR; van der Marel GA; Overkleeft HS; Lipford G; Offringa R; Melief CJ; van Boom JH; van der Burg SH; Drijfhout JW
Vaccine; 2004 Dec; 23(3):305-11. PubMed ID: 15530672
[TBL] [Abstract][Full Text] [Related]
12. Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines.
Moyle PM; Olive C; Ho MF; Pandey M; Dyer J; Suhrbier A; Fujita Y; Toth I
J Med Chem; 2007 Sep; 50(19):4721-7. PubMed ID: 17705361
[TBL] [Abstract][Full Text] [Related]
13. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours.
Chandy AG; Nurkkala M; Josefsson A; Eriksson K
Vaccine; 2007 Aug; 25(32):6037-46. PubMed ID: 17629599
[TBL] [Abstract][Full Text] [Related]
15. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.
Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M
J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
[TBL] [Abstract][Full Text] [Related]
17. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.
Liu B; Ye D; Song X; Zhao X; Yi L; Song J; Zhang Z; Zhao Q
Vaccine; 2008 Mar; 26(10):1387-96. PubMed ID: 18272260
[TBL] [Abstract][Full Text] [Related]
18. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
19. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
20. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
